A New Path After BCMA Therapies Fail
Bristol Myers Squibb announced on September 8, 2026, that its GPRC5D-targeting CAR T-cell therapy, arlocabtagene autoleucel, met its primary and key secondary endpoints in the registrational phase 2 QUINTESSENTIAL trial. The company confirmed that the single-infusion treatment showed a statistically significant and clinically meaningful improvement in overall response rate among patients with relapsed or refractory multiple myeloma who had already received at least four lines of prior therapy, including a BCMA-targeted agent. While Bristol Myers Squibb has not yet released the specific numerical data from this pivotal study, the topline success marks a significant step toward a potential FDA filing for a treatment option in a space where choices are currently limited.
This development is particularly relevant for patients who have exhausted standard lines of care. Multiple myeloma is a cancer of plasma cells, and while treatments have improved over the last decade, resistance remains a major challenge. The QUINTESSENTIAL trial focused on a specific group of patients who are quadruple-class exposed. This means they have been treated with all four main drug classes used in myeloma: immunomodulatory inhibitors, proteasome inhibitors, anti-CD38 therapies, and BCMA-targeted therapies. According to Lynelle Hoch, head of cell therapy at Bristol Myers Squibb, an increasing number of patients are becoming resistant to these therapies earlier in their treatment journey due to the frequent use of combination regimens in earlier lines. This creates a critical need for new therapeutic approaches that target different mechanisms of action.
How Arlo-cel Targets GPRC5D
Arlo-cel is an autologous chimeric antigen receptor (CAR) T-cell therapy. Unlike bispecific antibodies, which are infused directly, CAR T-cell therapies involve collecting a patient’s own T-cells, engineering them in a laboratory to recognize a specific protein on the surface of cancer cells, and then reinfusing them. In the case of arlo-cel, the T-cells are modified to target GPRC5D, a protein expressed on the surface of myeloma cells.
The choice of GPRC5D as a target is not arbitrary. It has become an established target in oncology. In 2023, Johnson & Johnson received accelerated FDA approval for its GPRC5DxCD3 bispecific antibody, Talvey (talquetamab), for use in fourth-line or later treatment of relapsed or refractory multiple myeloma. The success of Talvey validated GPRC5D as a viable target, but it also highlighted the need for diverse therapeutic modalities. Some myeloma cells stop producing BCMA, the target of previous therapies, rendering BCMA-directed drugs ineffective. By targeting GPRC5D, arlo-cel offers a distinct mechanism of action that may work in patients who have failed prior BCMA therapies.
Bristol Myers Squibb describes arlo-cel as a potential first-in-class GPRC5D-targeted autologous CAR T-cell therapy. The therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA. This designation allows for expedited development, providing the company with more frequent interactions with regulators and the potential for accelerated review if the therapy demonstrates substantial evidence of effectiveness.
Phase 1 Data: Durability and Response Rates
The foundation for the recent phase 2 success lies in the data from the phase 1 CC-95266-MM-001 trial, which was presented at the 2024 American Society of Hematology (ASH) Annual Meeting and subsequently published in Blood Advances. In this dose-escalation and expansion study, 84 adults with relapsed or refractory multiple myeloma were treated. The efficacy-evaluable population consisted of 79 patients.
At a median follow-up of 16.1 months, the overall response rate (ORR) in the overall population was 87%. This comprised a 53% complete response (CR) rate, a 23% very good partial response (VGPR) rate, and an 11% partial response (PR) rate. A complete response means that no detectable myeloma remains. In the subgroup of 23 patients who received the recommended phase 2 dose of 150 x 10^6 CAR T-cells, the ORR was even higher at 91%, with a 48% CR rate and a 22% VGPR rate.
The encouraging part of these early findings is the durability of the responses. The median progression-free survival was 18.3 months, and the median duration of response was 18.0 months. One-year overall survival reached 90%. Notably, responses were observed regardless of high-risk cytogenetics or prior treatment with BCMA-directed therapies. Susan Bal, MD, an associate professor at the University of Alabama at Birmingham and lead study author, noted that these outcomes were not affected by exposure to prior therapies. This suggests that arlo-cel may retain its efficacy even in patients who have been heavily pretreated with other immunotherapies.
Safety Profile and Side Effects
As with all CAR T-cell therapies, safety is a primary concern. In the phase 1 trial, any-grade treatment-emergent adverse events were reported in all patients. Grade 3 or 4 treatment-emergent adverse events occurred in 86% of all treated patients and 85% of patients who received the recommended phase 2 dose. These serious adverse events are common in this class of drugs and often include cytokine release syndrome and neurotoxicity, though the sources provided do not break down these specific incidences.
A unique aspect of arlo-cel’s safety profile is the on-target/off-tumor effects related to GPRC5D expression in healthy tissues. GPRC5D is expressed in the skin, nails, and oral mucosa. Consequently, patients experienced skin, nail, and oral adverse events. According to the data presented, these effects were transient in nature. Most toxicities were grade 1 or 2, indicating mild to moderate severity. No new safety signals were reported with the updated data presented at the ASH meeting. The safety profile observed in the phase 2 QUINTESSENTIAL trial was described by Bristol Myers Squibb as consistent with expectations.
Regulatory Path and Patient Access
The phase 2 QUINTESSENTIAL trial (NCT06297226) is the registrational study intended to support an FDA approval application. It met its primary endpoint of overall response rate and key secondary endpoints of complete response rate in patients who were quadruple-class exposed after four or more prior lines of therapy, as well as in patients with three or more prior lines. While the company announced topline success in September 2026, it withheld the specific numerical results at that time. This is a standard practice; detailed data is typically presented at major medical conferences or in peer-reviewed publications before a formal regulatory submission is made.
In parallel, the phase 3 QUINTESSENTIAL-2 study has been opened but is not yet recruiting. This study will compare arlo-cel with standard regimens in earlier-line patients. The goal of moving to phase 3 in earlier lines is to establish arlo-cel as a broader treatment option, not just a last resort. However, for patients currently in the later lines of therapy, the phase 2 data will be the primary basis for any initial FDA approval.
It is important to clarify that arlo-cel is not yet FDA approved. Patients with multiple myeloma who are looking for new options should discuss their eligibility for clinical trials with their hematologist-oncologist. Clinical trials often have specific inclusion and exclusion criteria, and participation may offer access to the therapy before it is commercially available.
The clinical context for arlo-cel is one of expanding options after the failure of BCMA therapies. While re-treating with a different BCMA-targeting drug can be effective, particularly if there is a gap of several months between attempts, some cancer cells stop producing BCMA altogether. In those cases, switching to a different target like GPRC5D is a logical next step. The data from arlo-cel suggests that this switch can yield deep and durable responses.
For patients and families navigating the complexities of multiple myeloma treatment, the landscape is slowly shifting. The availability of therapies targeting different antigens provides a safety net when one mechanism fails. The early findings suggest that arlo-cel is a viable option for heavily pretreated patients, with a manageable safety profile. However, as with any new therapy, individual results may vary, and the long-term outcomes are still being monitored.
The journey from phase 1 data to approved therapy can take time, involving regulatory review and potential labeling discussions. The RMAT designation may expedite this process, but it does not guarantee immediate approval. Patients should remain in close communication with their care teams to understand the current status of the drug and their own eligibility for trials.
The story of arlo-cel is part of a broader trend in oncology toward precision medicine, where treatments are matched to the specific molecular vulnerabilities of a patient’s cancer. By targeting GPRC5D, Bristol Myers Squibb is addressing a gap left by the saturation of BCMA-targeted therapies. The phase 2 success is a positive signal, but the full picture will emerge as more data is released and the drug moves through the final stages of regulatory review.
In the meantime, patients should not interpret the topline results as a guarantee of success for every individual. Clinical trial data reflects the average outcome of a group, and individual biology varies. Factors such as prior treatment history, disease burden, and overall health can influence response. The fact that arlo-cel worked in patients with high-risk cytogenetics is a particularly strong point, as these patients often have fewer options and poorer prognoses.
The medical community is watching the QUINTESSENTIAL-2 trial with interest. If arlo-cel proves effective in earlier lines, it could change the standard of care for multiple myeloma. For now, its role is defined by the phase 2 data: a potential lifeline for patients who have run out of standard options after BCMA therapy.
As always, the most important step for any patient is to talk to your doctor or oncologist. They can provide the most up-to-date information on clinical trials, explain the risks and benefits of new therapies, and help determine the best course of action based on your specific medical history. The data is promising, but personalized medical advice is essential.
Sources
- Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma | OncLive
- BMS eyes role for new CAR-T in post-BCMA multiple myeloma
- Arlo-Cel Generates Excitement, Moves Quickly to Phase 3 Studies for Multiple Myeloma | CGTlive®
- Phase I Evaluation of Arlocabtagene Autoleucel in RRMM
Photo: National Cancer Institute / Unsplash (Unsplash License)
